fidanacogene elaparvovec
AXP000255.1 · Viral vector gene therapy
- Platform
- AAVRh74var vector
- Targets
- F9
- Originator
- Spark Therapeutics
- Sponsor
- Pfizer
Names
| Name | Type | Source |
|---|---|---|
| fidanacogene elaparvovec | preferred name | curator |
| Beqvez | brand | fda |
| Durveqtix | brand | curator |
| PF-06838435 | former code | curator |
| SPK-9001 | former code | curator |
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus rh74 (variant capsid)
- Strain
- AAVRh74var
- Replication
- non replicating
- Modifications
- liver-directed expression cassette
- Transgenes
- F9 (R338L Padua variant)
- Route
- intravenous
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2024-04-25 | approved | Beqvez | Adults with moderate to severe haemophilia B on routine prophylaxis | source |
| EMA | EU | 2024-07-24 | withdrawn | Durveqtix | Severe and moderately severe haemophilia B; conditional authorisation withdrawn 2025-05-15 at the holder's request | source |
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05568719 | Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively | Recruiting | Phase 3 | 2022-12-28 | 2040-02-25 | 173 | Hemophilia A; Hemophilia B |
| NCT03861273 | A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B | Active not recruiting | Phase 3 | 2019-07-29 | 2022-11-16 | 51 | Hemophilia B |
| NCT03307980 | Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B | Terminated | Phase 2 | 2017-06-22 | 2026-07-23 | 21 | Hemophilia B |
| NCT02484092 | A Gene Therapy Study for Hemophilia B | Completed | Phase 2 | 2015-11-18 | 2019-04-08 | 15 | Hemophilia B |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41110511 | Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial. | Journal of thrombosis and haemostasis : JTH | 2026 | name in title: fidanacogene elaparvovec |
| PMID 41734390 | Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. | Blood advances | 2026 | cited by trial NCT03307980 |
| PMID 42941822 | Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B. | International journal of molecular sciences | 2026 | name in title: fidanacogene elaparvovec |
| PMID 40239068 | Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study. | The New England journal of medicine | 2025 | cited by trial NCT03307980 |
| PMID 40750723 | Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B. | Clinical pharmacokinetics | 2025 | cited by trial NCT02484092 |
| PMID 38863155 | Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec. | Thrombosis and haemostasis | 2024 | cited by trial NCT02484092 |
| PMID 39321362 | Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. | The New England journal of medicine | 2024 | cited by trial NCT03861273 |
| PMID 29211678 | Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. | The New England journal of medicine | 2017 | cited by trial NCT02484092 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40785174 | A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy. | Current gene therapy | 2026 | name in abstract: fidanacogene elaparvovec |
| PMID 41263376 | Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in title: fidanacogene elaparvovec |
| PMID 41381305 | Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies. | Blood reviews | 2026 | name in abstract: fidanacogene elaparvovec |
| PMID 41773269 | Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders. | Journal of blood medicine | 2026 | name in abstract: fidanacogene elaparvovec |
| PMID 42433651 | Overview of Patient-Reported Outcomes in Haemophilia Gene Therapy. | Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie | 2026 | name in abstract: SPK-9001 |
| PMID 42676001 | Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: fidanacogene elaparvovec |
| PMID 42947409 | Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: fidanacogene elaparvovec |
| PMID 42976908 | Patient-Relevant Questions on Gene Therapy for Haemophilia. | Hamostaseologie | 2026 | name in abstract: fidanacogene elaparvovec |
| PMID 42984386 | Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products. | Haematologica | 2026 | name in abstract: fidanacogene elaparvovec |
| PMID 39868419 | Gene-ius at work: Hemophilia B treatment enters a new era. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists | 2025 | name in abstract: fidanacogene elaparvovec |
| PMID 40156191 | The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in abstract: Beqvez |
| PMID 40488175 | Gene-based therapies for hemophilia. | Research and practice in thrombosis and haemostasis | 2025 | name in abstract: fidanacogene elaparvovec |
| PMID 41229950 | Role of Pharmacy Professionals in Gene Therapy Based on Adeno-Associated Viruses: Treatment of Hemophilia as a Template of Care. | The Canadian journal of hospital pharmacy | 2025 | name in abstract: fidanacogene elaparvovec |
| PMID 38472707 | Fidanacogene Elaparvovec: First Approval. | Drugs | 2024 | name in title: fidanacogene elaparvovec |
| PMID 38905534 | Beqvez - another gene therapy for hemophilia B. | The Medical letter on drugs and therapeutics | 2024 | name in title: Beqvez |
| PMID 33636038 | Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. | Journal of thrombosis and haemostasis : JTH | 2021 | name in abstract: fidanacogene elaparvovec |
Notes
Recombinant AAVRh74var capsid carrying the factor IX Padua (R338L) variant for haemophilia B. Approved in the US as Beqvez (2024-04-25) and in the EU as Durveqtix (conditional, 2024-07-24), which EMA has since renamed Beqvez, so its EPAR is now at .../EPAR/beqvez; the EU authorisation was withdrawn at Pfizer's request on 2025-05-15 for commercial reasons and the product was never marketed there. The capsid is the label's AAVRh74var, not the AAV-Spark100 name used in earlier literature.
How to cite
fidanacogene elaparvovec (AXP000255.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000255.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.